HAEMONETICS CORP — Director's Dealing 2012

May 3, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2012-05-01

Reporting Person: LINDOP CHRISTOPHER J (CFO & VP, Business Dev.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-01	Common Stock	P	264	$49.827	Acquired	13780	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$48.09	2014-01-25	Common Stock (40545)	40545	Direct
Non-Qualified Stock Option (right to buy)	$51.07	2014-10-24	Common Stock (21238)	21238	Direct
Non-Qualified Stock Option (right to buy)	$52.63	2015-10-23	Common Stock (49020)	49020	Direct
Non-Qualified Stock Option (right to buy)	$52.94	2016-10-27	Common Stock (22036)	22036	Direct
Non-Qualified Stock Option (right to buy)	$54.55	2015-10-22	Common Stock (21441)	21441	Direct
Non-Qualified Stock Option (right to buy)	$54.99	2017-10-27	Common Stock (25095)	25095	Direct
Non-Qualified Stock Option (right to buy)	$61.34	2018-10-25	Common Stock (24153)	24153	Direct

Footnotes

F1: Acquisition of shares of Common Stock pursuant to the Employee Stock Purchase Plan. Participant elected to purchase shares at least six months in advance of the effective date of the transaction.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the grant date.

F4: Grant to reporting person of right to buy shares of common stock vesting in annual increments over a 5 year period beginning on the first anniversary of the grant date.